SGLT-2 Inhibitor: Difference between revisions
(Created page with "==Administration== *Type: Diabetes medication *Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes ==...") |
(→Common) |
||
| Line 11: | Line 11: | ||
===Common=== | ===Common=== | ||
*UTI | *[[UTI]] | ||
*Genital candidiasis | *Genital candidiasis | ||
*Weight loss | *Weight loss | ||
Revision as of 03:19, 18 April 2017
Administration
- Type: Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Euglycemic DKA[1]
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule